CRON
Cronos Group Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$3.26
+0.00%Year over year
Reported trailing growth
- Revenue
- +86.4%
- EBITDA
- +195.2%
- EBIT
- +122.9%
- EPS
- +214.2%
- Free cash flow
- +573.2%
- Operating cash flow
- +174.2%
Forward estimates
Based on analyst estimates
- Revenue
- -9.8%
- EBITDA
- +2.1%
- EPS
- -69.7%
Three-year CAGR
- Revenue
- +19.8%
- EBITDA
- +93.3%
- EBIT
- +76.7%
- Net income
- —
- EPS
- —
- Free cash flow
- -97.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026